Cytokine Release Syndrome clinical trials at UCSF
1 research study open to eligible people
Cytokine release syndrome is when the body overreacts to certain treatments, causing severe inflammation. UCSF is studying a combination of drugs called Glofitamab, Gemcitabine, and Oxaliplatin in patients with difficult-to-treat lymphoma. This trial aims to better understand and optimize the treatment to manage these responses.
Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
open to eligible people ages 18 years and up
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
San Francisco, California and other locations
Last updated: